Loss of TRAIL-Receptors Is a Recurrent Feature in Pancreatic Cancer and Determines the Prognosis of Patients with No Nodal Metastasis after Surgery.

Autor: Gallmeier, Eike¹, Bader, Dominik C.¹, Kriegl, Lydia², Berezowska, Sabina², Seeliger, Hendrik³, Göke, Burkhard¹, Kirchner, Thomas², Bruns, Christiane³, De Toni, Enrico N.¹ Enrico.deToni@med.uni-muenchen.de

Publikováno v: PLoS ONE. Feb2013, Vol. 8 Issue 2, p1-10. 10p.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Loss of TRAIL-receptors is a recurrent feature in pancreatic cancer and determines the prognosis of patients with no nodal metastasis after surgery

Autor: Dominik C. Bader, Enrico N. De Toni, Lydia Kriegl, Sabina Berezowska, Burkhard Göke, Thomas Kirchner, Eike Gallmeier, Hendrik Seeliger, Christiane J. Bruns

Publikováno v: PLoS ONE, Vol 8, Iss 2, p e56760 (2013)
PLoS ONE
Gallmeier, Eike; Bader, Dominik C.; Kriegl, Lydia; Berezowska, Sabina Anna; Seeliger, Hendrik; Göke, Burkhard; Kirchner, Thomas; Bruns, Christiane; De Toni, Enrico N. (2013). Loss of TRAIL-receptors is a recurrent feature in pancreatic cancer and determines the prognosis of patients with no nodal metastasis after surgery. PLoS ONE, 8(2), e56760. Public Library of Science 10.1371/journal.pone.0056760

IntroductionAgonistic antibodies targeting TRAIL-receptors 1 and 2 (TRAIL-R1 and TRAIL-R2) are being developed as a novel therapeutic approach in cancer therapy including pancreatic cancer. However, the cellular distribution of these receptors in pri

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::979da755081f2d769396415edcca10a6
https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23460812/pdf/?tool=EBI